Dr. Reddy's launches first generic version of Bosulif in the US; stock in focus

Shares of Dr. Reddy's Laboratories

will be in focus on Monday, June 15, after the company announced the launch of Bosutinib Tablets 400 mg in the US, marking the first generic version of Bosulif to enter the market.

The launch strengthens Dr. Reddy's oncology portfolio and aligns with its strategy of expanding access to cost-effective treatment options for patients.

The company said the product was launched in collaboration with MSN Laboratories. Under the partnership, MSN handled the development and manufacturing of the medicine, while Dr. Reddy's holds exclusive marketing rights for the US market.

Bosutinib Tablets 400 mg was filed under the first-to-file category, making it eligible for 180 days of generic drug exclusivity in the US for this dosage strength. Such exclusivity provides the first generic entrant with a temporary period of limited competition, potentially supporting market share gains.

According to IQVIA data, sales of the reference drug Bosulif 400 mg stood at approximately $253.8 million in the US during the 12-month period ended April 2026.

Milan Kalawadia, CEO of North America at Dr. Reddy's Laboratories, said the launch reflects the company's focus on bringing important therapies to market quickly while improving affordability and access for patients and healthcare providers.

He added that the company remains committed to expanding its oncology offerings and strengthening partnerships across the healthcare ecosystem.

Bharat Reddy, Executive Director at MSN Laboratories, said the launch highlights the company's capabilities in developing, manufacturing and commercialising complex oncology products, while reinforcing its commitment to supplying affordable medicines globally.

Dr. Reddy's Laboratories shares ended Friday's session 0.24% lower at ₹1,272.90. The stock has gained around 2% so far in 2026.